Ignite Creation Date:
2024-05-06 @ 6:22 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05644743
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-12-09
First Post:
2022-11-30
Brief Title:
Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma
Sponsor:
Chengjun SuiMD
Organization:
Eastern Hepatobiliary Surgery Hospital
Study Overview
Official Title:
Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The clinical incidence of intrahepatic cholangiocarcinoma ICC is high and insidious and the prognosis of advanced patients is poor The clinical manifestations of traditional chemotherapy GC and emerging targeted therapy are different in most patients and there is still no effective scheme to evaluate the differences in individual patient reactivity Patient-derived tumor organoids PDO are 3D-cultured tissues based on tumor cell dryness that reproduce a variety of biological characteristics of parental tumors in vitro and have similar drug responsiveness to tumors in vivo This project plans to use clinical cases and optimized organoid culture system to first construct relevant organoids from unresectable ICC patient puncture samples Secondly based on the organoid model of intrahepatic cholangiocarcinoma the clinical efficacy of GC regimen was predicted and in vitro and in vivo drug screening was conducted to explore the guidance of patient-derived tumor organoids for clinical treatment Then multi-omics data of organoids and in vitro and in vivo drug efficacy evaluation model were used to explore the drug resistance genes of intrahepatic cholangiocarcinoma providing the basis for personalized drug screening and efficacy evaluation of intrahepatic cholangiocarcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None